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Abstract
TheEnhancerofZeste2(EZH2)protein hasbeen reportedtostimulatecellgrowthinsomecancersandisthereforeconsidered
to represent an interesting new target for therapeutic intervention. Here, we investigated a possible role of EZH2 for the
growth control of colon cancer cells. RNA interference (RNAi)-mediated intracellular EZH2 depletion led to cell cycle arrest of
colon carcinoma cells at the G1/S transition. This was associated with a reduction of cell numbers upon transient transfection
of synthetic EZH2-targeting siRNAs and with inhibition of their colony formation capacity upon stable expression of vector-
borne siRNAs. We furthermore tested whether EZH2 may repress the growth-inhibitory p27 gene, as reported for pancreatic
cancer. However, expression analyses of colon cancer cell lines and colon cancer biopsies did not reveal a consistent
correlation between EZH2 and p27 levels. Moreover, EZH2 depletion did not re-induce p27 expression in colon cancer cells,
indicatingthatp27repressionby EZH2 maybe cell- or tissue-specific. Whole genome transcriptome analysesidentified cellular
genes affected by EZH2 depletion in colon cancer cell lines. They included several cancer-associated genes linked to cellular
proliferation or invasion, such as Dag1, MageD1, SDC1, Timp2,a n dTob1. In conclusion, our results demonstrate that EZH2
depletion blocks the growth of colon cancer cells. These findings might provide benefits for the treatment of colon cancer.
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Introduction
The Enhancer of Zeste Homolog 2 (EZH2) protein is a core
component of the Polycomb Repressive Complex2 (PRC2) and
modifies transcription at the epigenetic level by affecting histone
and DNA methylation [1]. EZH2 is overexpressed in several
malignancies, including major human cancers, such as prostate
cancer, breast cancer, pancreatic cancer, renal cell carcinoma, or
cervical cancer [2–6].
There is experimental evidence that EZH2 can directly
contribute to carcinogenesis by acting as a bona fide oncogene.
Specifically, for certain cancer entities, it has been reported that
EZH2 stimulates cell proliferation, blocks apoptosis, promotes cell
invasion and metastasis, activates tumor angiogenesis, and induces
tumors in mouse models [2–11]. These findings suggest that EZH2
inhibition may represent an attractive novel strategy for epigenetic
cancer therapy [1,12].
More recently, however, there is also data suggesting that EZH2
could act as a tumor suppressor protein in certain tissues [13].
Homozygous inactivating EZH2 mutations were detected in a
portion of myeloid malignancies [14,15], raising the possibility that
EZH2 may either exert pro- or anti-oncogenic activities, in a cell
type-dependent manner [16]. Another level of complexity is added
by the detection of heterozygous EZH2 mutations in a portion of
lymphomas of germinal-center origin [13]. In this case, the mutant
protein appears to increase the level of H3K27 methylation, a
critical downstream target of EZH2, by acting in conjunction with
the wild-type protein expressed from the unmutated allele [17].
Colorectal cancer is the fourth most common cancer form in
humans. Each year, more than 1,200,000 individuals will develop
the disease and over 600,000 will die from it [18]. Despite the high
biomedical significance of this tumor, investigations of the EZH2
status and function in colon cancer cells are sparse and partly
contradictory. For example, whereas EZH2 was consistently
reported to be overexpressed in colon cancers, EZH2 expression
levels correlated positively [19], negatively [20,21], or not at all
[22], with the survival of colon cancer patients. Moreover, to our
knowledge, only one functional study investigated the role of
EZH2 for the growth of colon cancer cells, but failed to see an
effect upon EZH2 gene silencing [22]. This finding is in strong
contrast to the growth-promoting role of EZH2 reported for
several other cancer entities [2–6]. In the present work, we
addressed this issue by analyzing EZH2 expression in colon cancer
cells in vitro and in vivo, and by investigating the contribution of
EZH2 to the growth of colorectal cancer cell lines.
Results
Expression of EZH2 in colon cancer cells in vitro and RNA
interference-mediated EZH2 repression
In order to investigate the expression of EZH2 in colon cancer
cells in vitro, we analyzed a panel of twelve tumor-derived colon
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21651cancer cell lines by immunoblotting and qRT-PCR. All tested
cell lines expressed readily detectable amounts of EZH2 protein
(Figure 1A) and EZH2 mRNA (Figure 1B). For subsequent RNA
interference (RNAi) analyses, we generated three synthetic siRNAs
targeting different regions of the EZH2 transcript. All three
siRNAs efficiently blocked EZH2 expression (Figure 1C). Since
potential off-target effects of individual siRNAs can be reduced by
siRNA pooling [23,24], we also tested a pool consisting of all three
EZH2-targeting siRNAs. This siRNA pool also efficiently blocked
EZH2 expression (Figure 1C) and was used for further functional
analyses.
EZH2 repression results in G1 arrest and growth inhibition
of colon cancer cells
Next, we tested the effect of RNAi-mediated EZH2 repression
on the growth of HCT116, LoVo, and DLD1 colorectal cancer
cells. siRNA-treatment resulted in a strong reduction of EZH2
levels in all tested colon carcinoma cell lines and, as previously
Figure 1. EZH2 expression in colon cancer cell lines. A Immunoblot analysis of EZH2 protein expression. Tubulin, loading control. B qRT-PCR
analyses of EZH2 mRNA expression. Data are presented as fold differences in gene expression, normalized to a housekeeping gene index. Standard
deviations from two reverse transcription replicates are indicated. C Modulation of EZH2 protein expression by RNAi. EZH2 expression was
determined by immunoblot analysis 48 hours after transfection with EZH2-targeting siRNAs or control siRNAs, as indicated. siEZH2pool: pooled EZH2-
targeting siRNAs. Tubulin, loading control.
doi:10.1371/journal.pone.0021651.g001
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21651reported for other cells [7], in a concomitant decrease of cyclin D1
expression (Figure 2A).
Cell cycle analyses by fluorescence activated cell sorting (FACS)
were performed in parallel. They revealed a statistically significant
increase in G1 populations and a concomitant decrease in S phase
populations, upon EZH2 repression. Typical FACS curves are
shown in Figure 2B, a compilation of the results of three
independent experiments is depicted in Figure 2C. These results
indicate that EZH2 repression induces cell cycle arrest at the G1/S
boundary and therefore may act antiproliferative in colon cancer
cells.
To further address this issue, cell count analyses of colon cancer
cell lines were performed. RNAi-mediated inhibition of EZH2
expression led to a significant reduction of cell numbers, which was
clearly visible 48–72 hours following transfection of synthetic
siRNAs (Figure 3A), indicating that EZH2 silencing results in
growth inhibition of colon cancer cells.
To validate the antiproliferative effect of EZH2 inhibition in
colon cancer cells by an independent method, we performed
colony formation assays. Two different EZH2-targeting siRNAs
were stably expressed from selectable expression vectors in
HCT116, LoVo, DLD1, and RKO cells, for 13 to 15 days. Both
EZH2-targeting siRNAs led to a clear reduction of the colony
formation capacity of all tested colon cancer cell lines versus
control siRNA-treated cells (Figure 3B). Morphological aspects,
FACS profiles, and terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) analyses did not provide evidence for
increased apoptosis of colon cancer cells upon RNAi-mediated
EZH2 repression (data not shown).
Taken together, these results indicate that EZH2 depletion
induces cell cycle arrest in the G1 phase and inhibits the growth of
colon cancer cells.
Tissue Micro Array analysis of EZH2 expression in colon
adenomas and cancers
Previous studies have shown that EZH2 is significantly
overexpressed in colon cancers when compared to normal colon
tissue [19–22]. However, data comparing EZH2 expression in
benign colon adenomas versus colon cancer is, to our knowledge,
not yet available. We therefore performed immunohistochemical
analysesemploying a tissuemicroarrayencompassing 24adenomas,
25 G1 carcinomas, 24 G2 carcinomas, and 24 G3 carcinomas. In
comparison to colon adenomas, EZH2 expression was significantly
increased in colon carcinomas (Figs. 4A and 4B). Analyses of colon
cancers representing different degrees of histological dedifferentia-
tion (increasing from G1–G3) revealed a trend for a further increase
of EZH2 expression for less differentiated cancers, which, however,
was not statistically significant (Figure 4B).
EZH2 and p27 expression do not correlate in colon
cancer
The cyclin-dependent kinase inhibitor p27 (also named Kip1) is
a growth inhibitory protein that blocks cell cycle progression at the
G1/S transition [25]. In colon cancers, p27 levels are frequently
low [26,27]. Interestingly, it was recently reported that EZH2
depletion led to p27 re-expression in pancreatic cancer cells,
indicating that EZH2 may contribute to tumor cell proliferation
by repressing p27 [4]. In view of our findings that EZH2 promotes
cell proliferation and stimulates G1/S cell cycle progression of
colon cancer cells, we addressed the question whether p27 is
repressed by EZH2 in colon cancer as well.
Immunohistochemical analyses revealed that colon cancers
exhibited significantly decreased nuclear p27 and a trend for
reduced cytoplasmic p27 protein levels (Figure 5A), when
compared with colon adenomas. Within the cancer group,
increasing degrees of cancer cell dedifferentiation (G1–G3) showed
a statistically non-significant trend for a further decrease of p27
expression (Figure 5A). In general, these results are opposite to the
findings obtained for EZH2 expression (Figure 4B), raising the
possibility that EZH2 levels may negatively correlate with p27
levels. However, EZH2 and p27 levels did not significantly
correlate in individual cancers (n=68) on a per patient basis, i.e. in
tumors derived from the same patient (Figure 5B). This lack of
association applied for analyzing EZH2 amounts in relation to
both nuclear or cytoplasmic p27 expression levels (Spearman’s
rank correlation coefficients r=0.187, p=0.572 and r=20.0623,
p=0.613, respectively).
In line with these in vivo findings, the basal levels of EZH2
protein expression did not consistently correlate with p27 protein
or mRNA levels in colon cancer cell lines in vitro (Figure 6A and
6B). We also investigated whether p27 expression levels are
affected by EZH2 depletion in HCT116, LoVo, and DLD1 colon
cancer cells. If EZH2 blocks p27 expression, silencing of EZH2
should be linked to a re-increase of p27 expression, as has been
observed in pancreatic cancer cells [4]. In contrast, however,
efficient inhibition of EZH2 expression was not associated with a
substantial increase of p27 expression, neither at the protein
(Figure 6C) nor at the mRNA (Figure 6D) level, in colon cancer
cells. Cellular fractionation studies revealed that p27 is virtually
exclusively localized in the cytoplasm, in HCT116, LoVo, and
DLD1 cells. This subcellular distribution was also not detectably
altered by EZH2 depletion (Figure S1).
Transcriptome Analyses of Colon Cancer Cells upon EZH2
depletion
In order to identify possible target genes affected by EZH2
depletion in colon cancer cells, transcriptome analyses were
performed. To this end, LoVo and DLD1 cells were treated either
with the siRNA pool silencing EZH2 expression or with control
siRNA. Changes in the expression levels of cellular genes were
assessed by using a genome-wide microarray of approximately
25,000 genes. We observed significant changes of 2,235 genes in
DLD1 (1,095 upregulated, 1,140 downregulated) (Table S1) and of
379 genes in LoVo (280 upregulated, 99 downregulated) (Table
S2). The overlap consisted of 139 genes that were affected by
EZH2 depletion in both colon cancer cell lines (100 upregulated,
39 downregulated). A heatmap visualizing these 139 differentially
regulated genes is provided in Figure 7A, indicating high
concordance between the biological replicates. A detailed list of
these genes is provided in Table S3.
Functional annotation of the 139 genes by Ingenuity Pathway
Analysis revealed that 37 gene products have been associated with
cancer (Table 1). In regard of the molecular and cellular functions,
EZH2 depletion was found to affect several genes involved in the
control of cellular development, growth control, cellular move-
ment, and signaling (Table 1).
To validate the array data, we analyzed the expression of 5
cancer-associated genes, which were induced by EZH2 depletion
in the transcriptome analyses, by qRT-PCR: (i) Dag1 (Dystrogly-
can 1) encoding an adhesion molecule, which is frequently
underexpressed in colon cancer [28], (ii) MageD1 (Melanoma-
associated antigen family protein-D1) encoding an inhibitor of
proliferation and tumor cell invasion [29], (iii) SDC1 (Syndecan 1),
encoding a cell surface proteoglycan that inhibits cell invasion
[30], (iv) Timp2 (TIMP metallopeptidase inhibitor 2), encoding an
inhibitor of matrix metalloproteinases whose downregulation
correlates with the invasive potential of LoVo colon cancer cells
EZH2 in Colon Cancer
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21651Figure 2. EZH2 depletion leads to cell cycle arrest of colon cancer cell lines. A Immunoblot analyses of HCT116, DLD1, and LoVo cells
showing efficient downregulation of EZH2 expression by RNAi. Cyclin D1 levels are indicated. Tubulin, loading control. B Cell cycle analyses by FACS.
Cells were treated with two control siRNAs or with EZH2-targeting siRNAs. Percentages of cells in the G1, S, or G2/M phases of the cell cycle are
indicated. C Compilation of cell cycle analyses from three independent experiments. Standard deviations are indicated. Asterisks equal p#0.05,
double asterisks equal p#0.01, n.s. not significant.
doi:10.1371/journal.pone.0021651.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21651Figure 3. EZH2 depletion leads to growth inhibition of colon cancer cell lines. A Cell counts following transient transfection with synthetic
control siRNA (sicontr-1) or EZH2-targeting siRNAs (siEZH2 pool). Graphs represent relative cell numbers, at the indicated time points after siRNA
transfection. Cell numbers at transfection (time point 0) were set as 1.0. Experiments were performed in triplicates, standard deviations are indicated.
Asterisks equal p#0.05, n.s. not significant. B Colony formation assays. HCT116, LoVo, DLD1, and RKO cells were stably transfected with plasmids
expressing two different shRNAs against EZH2 (pCEP-shEZH2-1, pCEP-shEZH2-2) or two control shRNAs (pCEP-shluc or pCEP-shcontr-1). Experiments
were independently repeated at least thrice, with consistent results.
doi:10.1371/journal.pone.0021651.g003
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antiproliferative protein with tumor suppressive potential [32].
As observed for the microarray, all 5 genes were also significantly
induced by EZH2 depletion in the qRT-PCR analysis (Figure 7B),
further corroborating the transcriptome data.
Discussion
In the present study, we show that EZH2 depletion in colon
cancer cells (i) reduces cell cycle progression at the G1/S
boundary, (ii) decreases cell numbers in short term growth assays,
and (iii) blocks cell growth in long-term colony formation assays.
These results are consistent with a growth-promoting role for
EZH2 in colon cancer and are in contrast to a recent report
indicating that the growth of colon cancer cells is not affected by
siRNA-mediated EZH2 depletion [22].
A possible explanation for this discrepancy may be related to the
assays used to measure cell growth. The previous study relied on the
MTT assay that measures a metabolic activity (reduction of MTT
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to
formazan) [22]. This assay can be affected by many conditions,
e.g. metabolic changes, and can lead to the underestimation of
growth inhibitory effects [33–35]. In contrast, in the present study,
antiproliferative effects following EZH2 silencing were consistently
observed in three independent assays. Our findings thus indicate
that EZH2 stimulates the proliferation of colon cancer cells, as has
been reported for several other cancer entities [2–9,11].
The exact molecular mechanisms how EZH2 stimulates cell
proliferation are still largely unknown. As a crucial component of
the PRC2 transcriptional repressor complex, EZH2 may lead to the
repression of antiproliferative genes. An interesting study recently
demonstrated that EZH2 leads to the repression of the growth-
inhibitoryp27cellcycleregulatorgeneinpancreaticcancercells[4].
Since p27 acts at the G1/S transition - which we found to be
affected by EZH2 silencing in colon cancer cells - and since p27
levels are frequently low in colon cancers [26,27], we tested a
possible correlation between EZH2 and p27 levels in vivo and in vitro.
However, comparative analyses of EZH2 and p27 expression
did not exhibit a statistically relevant positive or negative linkage in
colon cancers in vivo, on a per patient basis. Moreover, EZH2
Figure 4. In vivo expression of EZH2 in colon carcinomas. A Immunohistochemical analyses of colon adenomas and colon cancer biopsies
representing increasing degrees of histological dedifferentiation (G1–G3). Black arrows: carcinoma; white arrows: connective tissue. Scale bars, 50 mm.
B Box plot of EZH2 protein expression. Expression levels of EZH2 were significantly increased in carcinomas when compared with adenomas
(p,0.001). Differences for EZH2 expression between G1, G2, and G3 carcinomas were not significant (p=0.185).
doi:10.1371/journal.pone.0021651.g004
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21651depletion did not result in a re-expression of p27 in colon cancer
cell lines in vitro, at time points where it resulted in highly increased
p27 expression in pancreatic cancer cell lines [4]. These findings
indicate that - in contrast to the situation in pancreatic cancer cells
- p27 levels are not critically regulated by EZH2 in colon cancer
cells. Thus, the spectrum of EZH2 target genes may vary in a
tissue- or cell-specific manner.
In order to get insight into the spectrum of genes, which are
affected by EZH2 depletion in colon cancer cells, we performed
whole genome transcriptome analyses in DLD1 and LoVo cells.
Among the 139 genes, which were significantly affected in both
cell lines, over one fourth is known to be cancer-associated. The
spectrum of affected genes is consistent with the hypothesis that
EZH2 is an important factor for development, proliferation
control, signaling, and movement/invasion [1,36]. Additional
work is required to analyze the exact mechanisms by which EZH2
may alter the expression of these genes and to study in detail their
possible contribution to the growth deregulation of colon cancer
cells. We corroborated the array data by expression analysis of 5
genes by qRT-PCR: Dag1, MageD1, SDC1, Timp2, and Tob1.I n
line with the transcriptome analysis, EZH2 silencing increased the
expression of all 5 genes in qRT-PCR analyses as well. These
findings suggest that EZH2 may repress these genes either directly
or indirectly, in colon cancer cells. All 5 genes are reported to
Figure 5. Relation between EZH2 and p27 expression in vivo.ABox plots of nuclear and cytoplasmatic p27 protein expression in colon
adenomas and carcinomas (G1–G3). Expression levels of nuclear p27 were significantly lower in carcinomas than in adenomas (p=0.026), cytoplasmic
p27 levels showed a similar trend, which, however, was not statistically significant (p=0.173). Differences for p27 expression between G1, G2, and G3
carcinomas were not significant. B Immunohistochemical staining of paired samples of colon cancers did not reveal a significant correlation between
EZH2 and p27 expression levels. Examples of 4 different cancers (I–IV) stained for EZH2 (upper panels) and p27 (lower panels), respectively. Scale bars,
50 mm.
doi:10.1371/journal.pone.0021651.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21651Figure 7. Altered gene expression in colon cancer cell lines upon EZH2 depletion. A Venn-Diagram and heatmaps of 139 genes that were
significantly affected at the transcript level by EZH2 depletion in both LoVo and DLD1 cells. Heatmaps were generated using hierarchical clustering.
Cells were either treated with siEZH2pool or sicontr-2. Four biological replicates were analyzed for each sample. Significantly upregulated genes are
indicated in yellow, significantly downregulated genes in blue. B qRT-PCR analyses to assess the expression of five genes that were affected by EZH2
depletion in the transcriptome analysis (see above). Indicated are the results from three independent experiments conducted in DLD1 cells. mRNA
levels are shown relative to sicontr-2-treated cells (arbitrarily set at 1.0). Standard deviations are indicated. Asterisks equal p#0.05, double asterisks
equal p#0.01.
doi:10.1371/journal.pone.0021651.g007
Figure 6. Relation between EZH2 and p27 expression in vitro.AEZH2 and p27 protein expression in colon cancer cell lines, assessed by
immunoblot analyses. Tubulin, loading control. B p27 mRNA expression, measured by qRT-PCR analyses. Data are presented as the fold differences in
gene expression, normalized to a housekeeping gene index. Standard deviations from two reverse transcription replicates are indicated. C
Immunoblot analyses after EZH2 depletion by RNAi. EZH2 and p27 levels are indicated. Tubulin, loading control. D qRT-PCR analyses after EZH2
depletion by RNAi. p27 and EZH2 mRNA levels are indicated relative to sicontr-1-treated cells (arbitrarily set at 1.0). Standard deviations of three
independent experiments are indicated.
doi:10.1371/journal.pone.0021651.g006
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their downregulation would thus be consistent with a possible
oncogenic effect of EZH2 in colon cancer.
Due to the growth-promoting role of EZH2 in various cancers,
inhibition of EZH2 is currently discussed as an attractive novel
strategy for cancer therapy [1,12]. Indeed, EZH2 inhibition by
siRNAs, or depletion of PRC2 components by the drug 3-
deazaneplanocin A (DZNep), exerted antioncogenic effects, by
blocking cell proliferation and/or inducing apoptosis [2–7,11,
37,38], by counteracting invasion and metastasis [9,10], and by
inhibiting tumor angiogenesis [8].
The finding in our study that EZH2 contributes to the
proliferation of colon cancer cells extends the spectrum of tumor
entities that may therapeutically benefit from EZH2 inhibition to
colon cancer. Considering EZH2 as a potential therapeutic target,
however, must take into account that EZH2 is also expressed in
normal tissues, including the proliferative cell layer of colon
crypts [22]. Importantly, EZH2 has been found to exert crucial
regulatory functions in several tissues, such as controlling the
differentiation of tissue-specific progenitor and stem cells [39–42].
Moreover, the recent observation that EZH2 may act as a tumor
suppressor in certain hematologic disorders [14,15,16] suggests
that EZH2 inhibition could even promote tumorigenesis, in some
tissues. Thus, interfering with EZH2 function as a therapeutic
strategy bears the risk to induce unwanted side effects and is likely
to require highly specific delivery of EZH2 inhibitors to their
target cells.
Materials and Methods
Cells and transfections
HCT116, DLD1, LoVo, WiDr, SW620, HCT15, RKO, T84,
Caco-2, and COLO205 colon carcinoma cell lines were a kind gift
from Dr. M. von Knebel Doeberitz (University of Heidelberg),
SW480 from Dr. S. Wiemann (German Cancer Research Center,
Heidelberg), and HT29 from the cell and tissue culture core
facility of the German Cancer Research Center, Heidelberg. Cells
were maintained in either DMEM (pH 7.2), RPMI, or McCoys
medium, supplemented with 10% FCS, 50 units/ml penicillin, and
50 mg/ml streptomycin sulfate.
Plasmids were transfected by calcium phosphate coprecipitation
[43] into HCT116 cells or by Fugene HD (Roche Diagnostics,
Mannheim, Germany) into DLD1, LoVo, and RKO cells.
Synthetic siRNAs were transfected with Dharmafect (Dharmacon,
Thermo Fisher Scientific, Lafayette, CO, USA) according to the
manufacturer’s protocol. In brief, cells were plated in 6-cm dishes
at 15% to 25% confluency. Dharmafect 4 and siRNAs (final
concentration of 100 nM) were both diluted in Opti-MEM I
reduced serum medium (Invitrogen, Carlsbad, CA, USA) and
mixed in a volume of 400 ml transfection solution.
Plasmids and synthetic siRNAs
siRNAs were either chemically synthesized (Dharmacon) or
expressed as shRNAs from pCEPsh, as previously described [44].
The following EZH2-targeting siRNAs were used: siEZH2-1 59-
GAAUGGAAACAGCGAAGGA-39 (predesigned siRNA from
Dharmacon), siEZH2-2 59-GACUCUGAAUGCAGUUGCU-39
[7], and siEZH2-3 59-GCUGAAGCCUCAAUGUUUA-39 (pre-
designed siRNA from Dharmacon). The siEZH2pool consisted of
all three siRNAs mixed at equimolar concentrations. The follow-
ing control siRNAs were used: sicontr-1 59-CAGUCGCGUUU-
GCGACUGG-39 [45], sicontr-2 59-UAGCGACUAAACACAU-
CAA-39 (predesigned siRNA from Dharmacon, containing at least
four mismatches to all known human genes), and siluc 59-CAU-
CACGUACGCGGAAUAC-39 (targeting Photinus pyralis luciferase
[46]).
RNA extraction, quantitative real-time reverse
transcription polymerase chain reaction (qRT-PCR), and
protein analyses
RNA was isolated as previously described [47] and resuspended
in RNAse free water. RNA concentrations were measured with
NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE
USA), at 260 nm. Reverse transcription of 1 mg RNA was perfor-
med by using the oligo-dT primer and ProtoScript M-MuLV Taq
RT-PCR Kit (New England Biolabs, Frankfurt, Germany)
according to the manufacturer’s protocol. Expression levels were
determined by real-time PCR with a 7300 Real-Time PCR
System detector (Applied Biosystems, Carlsbad, CA, USA), using
the SYBR green PCR Master Mix (Applied Biosystems), supple-
mented to 500 nM of each forward and reverse primer. EZH2
(NM_004456) expression was determined using the forward prim-
er 59-TTGTTGGCGGAAGCGTGTAAAATC-39 and reverse
primer 59-TCCCTAGTCCCGCGCAATGAGC-39 [48]. For de-
tection of p27
Kip1 (NM_004064) expression 59-GCCAGACGGG-
GTTAGCGGAG-39 was used as forward and 59-GAGGCCAG-
GCTTCTTGGGCG-39 as reverse primer. MageD1 (NM_00100
5333) expression was determined with primers 59-GGCTGTC-
CTCTGGGAGGCACT-39 and 59-GGGTTGCTGTTGGGCA-
CTCGT-39, Timp2 (NM_003255) expression with primers 59-
TCTACACGGCCCCCTCCTCG-39 and 59-TGGGGCAGCG-
CGTGATCTTG-39, SDC1 (NM_001006946) expression with pri-
mers 59-CGGCCCTGCCGCAAATTGTG-39 and 59-CCTCCA-
GGCCGGTGGGTTCT-39, Tob1 (NM_005749) expression with
primers 59-TGCAGCCTATGGAGGCCTCAA-39 and 59-CCC-
CTTGGGCCCGTGCATTTT-39, and Dag1 (NM_001165928)
expression with primers 59-GTCGTCGGGCGCTCATTTCGA-
39 and 59-CCAGCCGTGTAGCGCTCACTG-39. GAPDH and
HPRT1 primer sequences and cycling conditions have been
previously described [49]. The sizes of the PCR products were
initially verified by agarose gel electrophoresis and subsequently
checked by melting point analysis after each reaction. Relative
quantification was performed using the comparative Ct (2
2DDCt)
method [50]. Data are presented as the fold difference in gene
expression normalized to a housekeeping gene index (the
geometric mean of GAPDH and HPRT1 expression levels), and
relative to a calibrator sample. The housekeeping genes were
chosen among several tested housekeeping genes for normalization
of gene expression, since they exhibited equal amplification
efficiencies as our genes of interest. Statistical significance of
differences in measured variables between controls and treated
groups was determined by a two-sided paired t-test using the
Sigma Plot software (Systat Software Inc., San Jose, CA).
Differences were considered significant at p#0.05.
Total protein extracts were prepared 48 to 96 hours after
transfection, as described previously [51]. For cytosolic and
nuclear extract preparation, cells were resuspended in lysis buffer
(10 mM Tris, 10 mM NaCl, 1 mM EDTA, 0.5% NonidetH P-40,
pH 7.4) and incubated on ice. Intact nuclei were pelleted by
centrifugation and the cytosolic extract in the supernatant was
transferred. Nuclei were washed twice with lysis buffer containing
0.05% NonidetH P-40 and the nuclear proteins were extracted as
described for total protein extracts. For Western blot analyses, 20–
30 mg of protein extract were separated by 12.5% SDS-PAGE,
transferred to an Immobilon-P membrane (Millipore, Bedford,
MA, USA), and analyzed by enhanced chemiluminescence (GE
Healthcare, Buckinghamshire, UK). The following antibodies
were used: anti-EZH2 antibody (AC22, Cell Signaling, Danvers,
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Laboratories, Franklin Lakes, NJ, USA), anti-cyclin D1 antibody
(DSC6, Cell Signaling), and anti-alpha-tubulin antibody (CP06,
Calbiochem, Darmstadt, Germany).
Cell count and cell cycle analyses
For cell count analyses, total cell numbers were determined 48–
72 hours after transfection. Total cells per milliliter were
measured, using a Countess Cell Counter (Invitrogen).
For cell cycle analyses, cells were trypsinized 48 hours after
transfection, washed in ice-cold phosphate-buffered saline (PBS),
and fixed in 80% cold ethanol overnight at 220uC. Subsequently,
cells were pelleted, resuspended in PBS containing 1 mg/ml
RNAse A (Roche Diagnostics) and 25 mg/ml propidium iodide
(Sigma-Aldrich, Munich, Germany), and then incubated for
30 min at 37uC. Cell cycle analyses were performed using a
FACSCalibur (BD Biosciences, Heidelberg, Germany) with
CellQuest Pro software provided by the manufacturer. Apoptotic
cells were excluded and quantitation of the percentage of cells in
individual cell cycle phases was performed using FlowJo software
(Tree Star, Ashland, OR), applying the Dean-Jett-Fox model [52].
Statistical significance of differences in measured variables
between controls and treated groups was determined by a two-
sided paired t-test as described above.
Colony formation assay
For colony formation assays, cells were grown on 6 cm dishes
and transfected with individual pCEPsh vectors. Colonies were
fixed and stained with formaldehyde-crystal violet 13–15 days after
transfection and subsequent selection for hygromycin B (Sigma)
resistance.
Tissue Micro Array
A tissue microarray (TMA) containing tissue samples derived
from tubular adenomas (n=30) and G1 (n=30), G2 (n=30), and
G3 (n=30) colorectal adenocarcinomas was analyzed. All tissue
samples were obtained from the Tissue Bank of the National
Center for Tumor Diseases (NCT) Heidelberg after approval by
the ethics committee of the University of Heidelberg.
For the creation of the TMA, representative tissue blocks were
selected as donor blocks. Sections were cut from each donor block
and stained with Hematoxylin and Eosin. Then, a morphologically
representative region was chosen from each tissue sample. One
cylindrical core tissue specimen per block (diameter 0.6 mm) was
punched from these regions and arrayed into the recipient paraffin
block using a semiautomatic system Tissue Arrayer MTA-1
(AlphaMetrix, Ro ¨dermarkt, Germany).
Immunohistochemistry
The TMA slides were dewaxed and rehydrated using xylene and a
series of graded alcohols, followed by heat induced antigen retrieval
using a target retrieval solution (S2031, DakoCytomation, Glostrup,
Denmark) in a pressure cooker for 10 min. Immunohistochemical
staining was performed on an automated staining system (Techmate
500, DakoCytomation) with a mouse anti-EZH2 antibody (1:20,
612667, BD Transduction Laboratories) for 30 min, and an mouse
anti-p27 antibody (1:150, 610242, BD Transduction Laboratories)
for 30 min. An avidin-biotin-complex peroxidase technique using
aminoethylcarbazole for visualisation and Hematoxylin for counter-
staining was applied. According to the manufacturers’ instructions,
the following solutions were used: ChemMate Detection Kit (K5003,
DakoCytomation),ChemMate BufferKit(K5006,DakoCytomation)
and, for reduction of non-specific avidin/biotin-related staining, the
Avidin/Biotin Blocking Kit (SP-2001, Vector Laboratories, Burlin-
game, USA). Reactive infiltrating lymphocytes, which express
detectable amounts of EZH2 protein, served as a internal positive
control [53]. As a negative control for the immunohistochemical
staining procedure, the primary antibody was omitted, with all other
experimental conditions kept constant.
For immunohistochemical measurement of EZH2 expression,
the frequency of nuclear staining was evaluated. p27 staining was
determined separately for nuclear and cytoplasmic expression.
Due to insufficient tumour tissue or fixation artefacts, which
interfered with immunohistochemical staining, 23 cases for EZH2-
staining and 18 cases for p27-staining were excluded from further
analyses. The arrays were independently scored by two research-
ers, blinded for tissue annotation. For the few instances of
discrepant scoring, a consensus score was determined. Box plots
were drawn as described in [54]. The association of p27 and
EZH2 expression and histological grading (Adenoma, G1, G2,
G3) was analyzed using a two-stage approach. First the two-sided
Jonckheere-Terpstra test was applied. If a statistically significant
trend was found (i) the Mann-Whitney test was used to compare
between adenomas and carcinomas and (ii) the Jonckheere-
Terpstra test was applied to the subgroup of carcinomas to test for
a trend according to histological grading. To measure the
correlation of p27 and EZH2 expression in colon carcinomas
Spearman’s rank correlation coefficient was calculated. A result
was considered as statistically significant, if the p value was smaller
than or equal to 5%. All statistical analyses were performed within
the R statistical software environment (R version 2.11.1) using the
R package coin, version 1.0-11.
Transcriptome analyses
For gene expression analysis, we used the whole genome
expression microarray SentrixH HumanHT-12 v4 expression bead
chip (IlluminaH, San Diego, CA, USA) encompassing 47,231
features. The experiments were performed at the Genomics and
Proteomics Core Facility of the German Cancer Research Center,
Heidelberg, using concentrations of 50 ng/ml RNA for each
sample and following the protocols recommended by the supplier.
Expression levels were analyzed 48 hours post transfection for
DLD1 cells and 72 hours post transfection for LoVo cells.
Statistical analysis was performed using the statistical computing
environment R [55]. Briefly, the gene expression profiles were
normalized using quantile normalization and differentially ex-
pressed genes were determined using a moderated t-statistic [56].
All p-values were corrected for multiple testing, and genes showing
a false discovery rate [57] p#0.05 were considered as significantly
deregulated. The statistical analysis was performed for each cell
line separately and for further analysis only the genes that were
significantly affected in both cell lines were used. The functional
analyses were generated through the use of IPA (Ingenuity
Systems, www.ingenuity.com).
Supporting Information
Figure S1 Subcellular localization of p27 in colon cancer
cells. Immunoblot analysis of p27 and EZH2 in cytoplasmic and
nuclear extracts prepared from colon cancer cells. Cells were
harvested 48 hours following treatment with control siRNAs
(sicontr-1 and sicontr-2) or siEZH2 pool. Fractionation controls:
Lamin A/C (nuclear protein) and Tubulin (cytoplasmic protein).
(TIF)
Table S1 Transcripts significantly affected upon EZH2
depletion in DLD1 cells.
(XLS)
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Table S3 Transcripts significantly affected upon EZH2
depletion in both LoVo and DLD1 cells.
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